Algernon Pharmaceuticals Inc (AGNPF)

[Money $hot]

Tsk Tsk Tsk

One Must Find Their Sunday Bli$$

Global Pharmaceuticals Industry Analysis and Trends 2023

As per the research, the global pharmaceutical industry will we worth USD 1.57 trillion by 2023. The growth in this market is predicted on the basis of various factors like market drivers, current and upcoming trends, current growth pattern, and market challenges.

North America is expected to retain it’s leading position in the global pharmaceuticals market with market share of 45.33% in 2023 improving on it’s market share compared to 2017. Europe on the contrary is expected to see a decline in it’s market share compared to 2017 and be worth 20.24% of global pharma industry in 2023. Asia Pacific pharmaceuticals market is expected to retain it’s second position with a market share of 24.07% in 2023. Latin America and Middle East and Africa (MEA) are expected to retain 7.53% and 2.96% market share of global pharmaceuticals market in 2023.

Ur not understanding the global significance/acceptance of a drug approval by the FDA. Christopher Moreau (CEO) told us any data readout from the South Korea "Investigator Lead" study could not be utilized for the FDA clinical trial. The key to the global market runs through the FDA. South Korea and Japan are the only two countries that can do whatever they want with Ifenprodil inside their respective borders. They cannot export the drug for sale outside of their borders.

Anyone can study this or that with Ifenprodil. At the end of the day it's all about clinical trials registered in black and white @ clinicaltrials.gov. Go out to the clinicaltrials.gov website and search Ifenprodil. The entire FDA history of Ifenprodil registers a total of 3 clinical trials. 2 clinical trials by Algernon , and 1 clinical trial in Japan for PTSD. The PTSD trial was completed 16 months ago and counting. If the PTSD readout was successful it would have moved to Phase 3. Clearly, it was not and did not.

As I stated in my previous re-PLIES, once Ifenprodil is FDA approved for any disease indication, Ifenprodil will be off limits to the rest of Pharma World outside of South Korea and Japan. Based on the market research quoted above, the vast majority (more than 90%) of the global market for Ifenprodil is wide open. South Korea and Japan make up less than 10% of the Asia pharmaceutical market. I posted that information in a previous post that I'm not going back to find.

All In All, if what you seek on message boards is not adequate, use your skills to get the answers you seek directly from management - if not already. At this juncture it's all about getting to data readout(s). Your focus is on something beyond Algernon's care or control. Meaning, ultimately doesn't matter what anyone else is doing with Ifenprodil. Algernon has Ifenprodil on lock with its preclinical development, research, timelines, and filed patents.

The human clinical trial data is the final piece of the puzzle.



References:
https://www.globenewswire.com/news-release/2020/01/17/1972092/0/en/Global-Pharmaceuticals-Industry-Analysis-and-Trends-2023.html#:~:text=North%20America%20is%20expected%20to,market%20share%20compared%20to%202017.
https://clinicaltrials.gov/ct2/results?cond=&term=ifenprodil&cntry=&state=&city=&dist=


Meanwhile...

The Ritz-Carlton on the West Coast is heavenly bli$$.

The flight tonite to Vegas is all about raising holy hell.

I'm checkin out n cashin in with some Boss Friends.

Peace 2x,

/////AMG

Outro